Introduction Global Markets Direct’s, 'Schizophrenia - Pipeline Review, H1 2012', provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on ...

more

BMI View: Estonia’s pharmaceutical market will remain of marginal interest to multinationals given its small population and a modest growth outlook. We expect the market to post a five-year compound annual growth rate (CAGR) of 5.07% in local currency terms through to 2016, with the following ...

more

Introduction Global Markets Direct’s, 'Schizophrenia - Pipeline Review, H2 2012', provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on ...

more

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules”, which provides ...

more

Introduction Global Markets Direct’s, 'Schizophrenia - Pipeline Review, Q1 2011', provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on ...

more

Alkermes, Inc. (ALKS) - Financial and Strategic SWOT Analysis Review Summary Alkermes, Inc., (Alkermes) is a publicly traded biotechnology company. It is engaged in developing and manufacturing of extended-release injectable, pulmonary, and oral products for the treatment of prevalent, ...

more

Cannasat Therapeutics, Inc. (Cannasat) publicly held clinicla stage pharmaceutical comapany, that is engaged in the discovery and development of therapeutics for the treatment of neuropathic pain, schizophrenia, chemotherapy-induced nausea and vomiting and other CNS related disorders. The ...

more

Allon Therapeutics Inc. (Allon), formerly Neuro Discovery Inc. is a clinical-stage biotechnology company, engaged in the development of the first drugs that impact the progression of neurodegenerative diseases and disorders. The company is focused on developing neuroprotective therapeutic ...

more

Biotie Therapies Corp. (Biotie) is a biotechnology company, engaged in the discovery and development of therapeutics for the treatment of central nervous system and inflammatory diseases. The company's develops pipeline products which includes, Nalmefene is an opioid receptor antagonist for ...

more

Memory Pharmaceuticals Corp. (Memory Pharmaceutical) is a biopharmaceutical company, engaged in the discovery and development of drug candidates for the treatment of central nervous system (CNS) disorders. The company develops new therapies for neurological diseases such as Alzheimer’s ...

more